Loading clinical trials...

Antidiabetic Potential of Galician High-phenolic Extra Virgin Olive Oils in Patients With Type 2 Diabetes Mellitus. | Clinical Trials | Clareo Health

COMPLETEDNA

Antidiabetic Potential of Galician High-phenolic Extra Virgin Olive Oils in Patients With Type 2 Diabetes Mellitus.

Antidiabetic Potential of Galician High-phenolic Extra Virgin Olive Oils in Patients With Type 2 Diabetes

NCT06757751•Fundacin Biomedica Galicia Sur

View on ClinicalTrials.gov

Summary

Since Galician virgin olive oils have a high content of bioactive phenolic compounds and these are attributed to a large part of the healthy properties of the Mediterranean Diet, our starting hypothesis is that these olive oils could attenuate insulin resistance, improving glycemic control in terms of fasting plasma glucose and/or glycated hemoglobin and insulin sensitivity.

Eligibility

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosed with type 2 diabetes mellitus for at least 1 year prior to inclusion.
•Older than 18 years old
•Current treatment with diet and/or oral hypoglycemic agents (biguanides, thiazolindiones, α-glucosidase inhibitors, iDPP4, aGLP-1, iSGLT2).
•Body mass index ≥ 25 kg/m2 and \< 40 kg/ m2.

Exclusion Criteria

•Patients on treatment with insulin, SU or rapid-acting insulin secretagogues.
•History of severe ketosis or hyperglycemic decompensation.
•Pregnancy, pregnancy planning or breastfeeding.
•Body mass index ≥ 25 kg/m2 and \< 40 kg/m2.
•Difficulty or great inconvenience in changing eating habits or a low predicted probability of changing eating habits.
•Serious medical condition that may affect the person's ability to participate in a nutritional intervention study (e.g., digestive disease with fat intolerance, malignant disease, or significant neurological, psychiatric, or endocrine disease).
•Any other medical condition considered to limit survival to less than 1 year.
•Immunodeficiency or HIV positive status.
•Illegal drug use, chronic alcoholism or problematic alcohol use or total daily alcohol intake \> 80 g/d.
•Participation in any clinical trial or use of any investigational drug within the past year.
+1 more criteria

Locations (1)

Beatriz Cancho Grande

Ourense, Spain

Key Dates

Start Date

April 30, 2021

Primary Completion Date

July 22, 2022

Completion Date

September 30, 2022

Last Updated

January 6, 2025

Enrollment

116

ACTUAL participants

Conditions

Diabetes Mellitus, Type 2

Interventions

EVOO diet supplement

DIETARY_SUPPLEMENT

PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents

NCT06959901

Obesity and Diabetes Mellitus, Type 2Diabetes Prevention

View study

RECRUITINGNA

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

NCT06574035

Diabetes Mellitus, Type 2Depressive Symptoms+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 6, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Antidiabetic Potential of Galician High-phenolic Extra Virgin Olive Oils in Patients With Type 2 Diabetes Mellitus.

Inclusion Criteria

Exclusion Criteria

PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes

Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use

Prediction of Heart Failure and Cognitive Decline in Type 2 Diabetes

Implementing Scalable, PAtient-centered, Team-based, Technology-enabled Care for Adults With Type 2 Diabetes (iPATH)